Background: This study compared the effect of antihypertensive treatment with valsartan or ramipril on atrial fibrillation (AF) recurrence, on P-wave dispersion, (PWD) and on serum procollagen type I carboxy terminal peptide (PIP).
Methods: A total of 369 mild hypertensive (systolic blood pressure (SBP) >140 and/or 90 < diastolic blood pressure (DBP) < 110 mm Hg) outpatients in sinus rhythm but with at least two episodes of AF in the previous 6 months were randomized to valsartan (n = 122), ramipril (n = 124), or amlodipine (n = 123) for 1 year. Clinic blood pressure (BP) and a 24-h electrocardiogram (ECG) were evaluated monthly. Patients were asked to report any episode of symptomatic AF and to perform an ECG as early as possible. PWD and serum PIP levels were evaluated before and after each treatment period.
Results: SBP and DBP were significantly reduced by the three treatments (P < 0.001). A total of 46 (47.4%) patients treated with amlodipine had a recurrence of AF as did 26 (27.9%) patients treated with ramipril (P < 0.01 vs. amlodipine) and 16 (16.1%) patients treated with valsartan (P < 0.01 vs. amlodipine and P < 0.05 vs. ramipril). The Kaplan-Meyer analysis showed a significant reduction of AF episodes in the valsartan group (P = 0.005 log-rank test) as well as in the ramipril group (P = 0.021), even if at a lesser degree. PWD values were significantly reduced by ramipril (-4.2 ms, P < 0.05) and even more by valsartan (-11.2 ms, P < 0.01), the difference being significant (P < 0.01). Serum PIP levels were reduced by ramipril (-49.7 microg, P < 0.001) and valsartan (-49.3 microg, P < 0.001).
Conclusions: Despite similar BP lowering, valsartan and ramipril were more effective than amlodipine in preventing new episodes of AF, but the effect of valsartan was greater than that of ramipril. This could be related to the greater PWD reduction observed with valsartan.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/ajh.2008.217 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sex differences in cardiac structure and function following acute myocardial infarction: Insights from the PARADISE-MI echocardiographic substudy.
Eur J Heart Fail
September 2024
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Article Synopsis
- The study investigates differences between men and women in heart function after a heart attack (MI) to understand why women have higher rates of hospitalization for heart failure.
- It analyzes echocardiographic data from 544 patients in the PARADISE-MI trial to assess heart function pre and post-MI, focusing on parameters like left ventricular ejection fraction (LVEF) and chamber sizes.
- Although women showed better heart function indicators at the start, the study found that the changes over 8 months and the relationship between heart function metrics and clinical outcomes were similar for both sexes.
Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MI.
Eur J Heart Fail
September 2024
Harvard Medical School, Boston, MA, USA.
Article Synopsis
- The study examined the impact of two medications, sacubitril/valsartan and ramipril, on short-term kidney function changes in patients experiencing acute myocardial infarction (MI), focusing on serum creatinine levels.
- In a trial with 5,661 patients, it was found that those taking sacubitril/valsartan had a slightly higher likelihood of experiencing initial increases in serum creatinine compared to those taking ramipril.
- However, acute changes in creatinine levels from either medication did not correlate with worse long-term cardiovascular outcomes or significant changes in kidney function, suggesting the initial increases might not indicate long-term risks.
Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trials.
Eur J Clin Pharmacol
August 2024
Southern Arizona VA Health Care System, 3601 S. 6th Ave, Tucson, AZ, 85723, USA.
Purpose: The objective of this meta-analysis is to determine how sacubitril/valsartan (SV) compares to equivalent and sub-equivalent angiotensin receptor blockers (ARB) or angiotensin-converting enzyme inhibitors (ACEI) in patients with heart failure with reduced ejection fraction (HFrEF).
Methods: The databases of PubMed and EMBASE were used to identify those randomized controlled trials which compared SV to ARB/ACEI in patients with HFrEF. Only those trials that reported outcomes regarding total mortality, cardiovascular mortality, and worsening heart failure were considered.
Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment.
N Engl J Med
April 2024
From the Montreal Heart Institute, University of Montreal, Montreal.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!